• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

存在缺失观测值的II期临床试验中多重缓解率的估计

Estimation of multiple response rates in phase II clinical trials with missing observations.

作者信息

Chang Myron

机构信息

Division of Biostatistics, Department of Epidemiology and Health Policy Research, College of Medicine, University of Florida, Gainesville, Florida 32608, USA.

出版信息

J Biopharm Stat. 2009 Sep;19(5):791-802. doi: 10.1080/10543400903105182.

DOI:10.1080/10543400903105182
PMID:20183444
Abstract

Responses are often correlated in clinical trials. A patient who is not evaluable for a response may still provide some information to the response through his or her status on other responses. Under the assumption of missing at random, we propose the utilization of a self-consistent estimator. We show that the proposed estimators are more efficient than the conventional estimators by asymptotic relative efficiency and simulation study. An example from a Phase II clinical trial on children with chronic myelogenous leukemia is provided.

摘要

在临床试验中,反应往往是相关的。一个对反应不可评估的患者仍可能通过其在其他反应上的状态为反应提供一些信息。在随机缺失的假设下,我们提出使用一种自洽估计量。我们通过渐近相对效率和模拟研究表明,所提出的估计量比传统估计量更有效。文中给出了一项针对慢性粒细胞白血病儿童的II期临床试验的例子。

相似文献

1
Estimation of multiple response rates in phase II clinical trials with missing observations.存在缺失观测值的II期临床试验中多重缓解率的估计
J Biopharm Stat. 2009 Sep;19(5):791-802. doi: 10.1080/10543400903105182.
2
A simple and efficient bias-reduced estimator of response probability following a group sequential phase II trial.一种用于成组序贯II期试验后反应概率的简单有效且偏差减小的估计量。
J Biopharm Stat. 2005;15(5):773-81. doi: 10.1081/BIP-200067771.
3
Optimal two-stage designs allowing flexibility in number of subjects for phase II clinical trials.在II期临床试验中允许受试者数量具有灵活性的最优两阶段设计。
J Biopharm Stat. 2009 Jul;19(4):721-31. doi: 10.1080/10543400902964167.
4
Continuous toxicity monitoring in phase II trials in oncology.肿瘤学II期试验中的连续毒性监测
Biometrics. 2005 Jun;61(2):540-5. doi: 10.1111/j.1541-0420.2005.00311.x.
5
Bayesian optimal designs for a quantal dose-response study with potentially missing observations.用于具有潜在缺失观测值的定量剂量反应研究的贝叶斯最优设计。
J Biopharm Stat. 2006;16(5):679-93. doi: 10.1080/10543400600860501.
6
Estimating cumulative probabilities from incomplete longitudinal binary responses with application to HIV vaccine trials.从不完全纵向二元反应估计累积概率及其在HIV疫苗试验中的应用。
Stat Med. 2003 Feb 15;22(3):463-79. doi: 10.1002/sim.1334.
7
Supplementary analysis of probabilities at the termination of a group sequential phase II trial.成组序贯II期试验结束时概率的补充分析。
Stat Med. 2005 Apr 15;24(7):1009-27. doi: 10.1002/sim.1990.
8
Inference methods for saturated models in longitudinal clinical trials with incomplete binary data.具有不完全二元数据的纵向临床试验中饱和模型的推断方法。
Pharm Stat. 2006 Oct-Dec;5(4):295-304. doi: 10.1002/pst.233.
9
Estimation of the risk difference under a noncompliance randomized clinical trial with missing outcomes.在存在结局数据缺失的不依从随机临床试验中风险差异的估计
J Biopharm Stat. 2008;18(2):273-92. doi: 10.1080/10543400701697166.
10
Interval estimation of binomial proportion in clinical trials with a two-stage design.两阶段设计的临床试验中二元比例的区间估计。
Stat Med. 2008 Jan 15;27(1):15-35. doi: 10.1002/sim.2930.